Crossmark

70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study

Crossref DOI link: https://doi.org/10.1007/s10549-024-07496-3

Published Online: 2024-09-30

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Verreck, Eline E. F.

Kuijer, Anne

van Steenhoven, Julia E. C.

Volders, José H.

van der Velden, Annette W. G.

Siesling, Sabine

Timmer-Bonte, Anja N. H.

Smilde, Tineke J.

Imholz, Alex L. T.

Blanken-Peeters, Charlotte F. J. M.

de Valk, Bart

Vrijaldenhoven, Suzan

Lastdrager, Willem B.

Haringhuizen, Annebeth W.

Hunting, Jarmo C. B.

Hovenga, Sjoerd

Nieboer, Peter

Zuetenhorst, Hanneke M.

Tetteroo, Geert W. M.

Smorenburg, Carolien H.

van Maaren, Marissa C.

van Dalen, Thijs
License Information

Text and Data Mining valid from 2024-09-30

Version of Record valid from 2024-09-30
More Information

Article History

Received: 6 June 2024

Accepted: 11 September 2024

First Online: 30 September 2024

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below